Binds Expression Product Of Cancer-related Gene Or Fragment Thereof (e.g., Oncogene, Proto-oncogene, Etc.) Patents (Class 530/387.7)
-
Publication number: 20090222931Abstract: A newly identified oncogene with kinase-domain (NOK) and its encoded polypeptide, and vectors, fusions, host cells and transgenic animals comprising the said nucleotide sequence. Furthermore, the present invention also describes the methods for diagnosing diseases including tumor and the methods for screening agents capable of inhibiting the occurrence and/or metastasis of tumor.Type: ApplicationFiled: May 13, 2004Publication date: September 3, 2009Applicant: TSINGHUA UNIVERSITYInventors: Li Liu, Xinyuan Fu, Zhijie Chang, Shuping Zhang
-
Patent number: 7582736Abstract: This invention provides novel prostate cancer specific internalizing human antibodies. The antibodies are useful by themselves to prevent growth and/or proliferation of prostate cancer cells. The antibodies can also be formulated as chimeric molecules to direct an effector (e.g. a cytotoxin, an imaging reagent, a drug, etc.) to a prostate tumor site.Type: GrantFiled: January 10, 2008Date of Patent: September 1, 2009Assignee: The Regents of the University of CaliforniaInventors: Bin Liu, James D. Marks
-
Publication number: 20090214542Abstract: The present invention relates to novel sequences for use in detection, diagnosis and treatment of cancers, especially lymphomas. The invention provides cancer-associated (CA) polynucleotide sequences whose expression is associated with cancer. The present invention provides CA polypeptides associated with cancer that are present on the cell surface and present novel therapeutic targets against cancer. The present invention further provides diagnostic compositions and methods for the detection of cancer. The present invention provides monoclonal and polyclonal antibodies specific for the CA polypeptides. The present invention also provides diagnostic tools and therapeutic compositions and methods for screening, prevention and treatment of cancer.Type: ApplicationFiled: September 24, 2003Publication date: August 27, 2009Inventors: David W. Morris, Marc S. Malandro
-
Patent number: 7579445Abstract: The invention is an apparatus and method for the treatment of prostate cancer, and involves administering an antibody that specifically binds with prostate antigen.Type: GrantFiled: October 14, 2004Date of Patent: August 25, 2009Assignee: AltaRex Medical Corp.Inventors: Beatrice Leveugle, Ragupathy Madiyalakan, Antoine A. Noujaim, Birgit C. Schultes
-
Publication number: 20090208483Abstract: An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of DR5 and DR4 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth.Type: ApplicationFiled: August 7, 2008Publication date: August 20, 2009Applicant: THE UAB RESEARCH FOUNDATIONInventors: Tong Zhou, Robert P. Kimberly, William J. Koopman, Albert F. LoBuglio, Donald J. Buchsbaum
-
Publication number: 20090208487Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.Type: ApplicationFiled: February 23, 2007Publication date: August 20, 2009Applicant: Elan Pharmaceuticals, Inc.Inventors: Dale B. Schenk, Kate Dora Games, Manuel J. Buttini, Tamie J. Chilcote, Edward Rockenstein, Eliezar Masliah
-
Patent number: 7576187Abstract: An isolated polynucleotide at least 60% homologous to SEQ ID NO: 1, 3, 5 or 18 encoding a SARP polypeptide; vectors comprising a polynucleotide sequence encoding at least 11 consecutive amino acids of ?SARP polypeptide; a host cell transformed with an isolated polynucleotide or vector; antibodies specific for SARP and use of such polynucleotides and antibodies in diagnostic and therapeutic method. Therapeutic uses of antibodies and polynucleotides of sarp. Methods for treating diseases related to the regulation of SARP expression in tissue and bodily fluid samples, including cancers.Type: GrantFiled: July 14, 2006Date of Patent: August 18, 2009Assignee: Genentech, Inc.Inventors: Samuil Umansky, Hovsep Melkonyan
-
Publication number: 20090202530Abstract: The invention relates to genetic products the expression of which is associated with cancer diseases. The invention also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases.Type: ApplicationFiled: September 6, 2006Publication date: August 13, 2009Inventors: Ugur Sahin, Özlem Türeci, Michael Koslowski, Dirk Usener
-
Publication number: 20090203538Abstract: It is intended to provide a method whereby a plural number of antibodies against cell surface antigens are quickly classified and to provide a method whereby antigens of the thus classified antibodies are quickly identified. Further, it is intended to provide a method of promoting the utilization of the useful data obtained by the above methods. Furthermore, it is intended to provide an antibody which is effective in treating or diagnosing cancer.Type: ApplicationFiled: January 9, 2009Publication date: August 13, 2009Applicant: Institute for Antibodies Co., Ltd.Inventors: Atsushi Sugioka, Mototaka Sugiura, Yasushi Akahori, Nobuhiro Hayashi, Akihiko Takasaki, Miwa Morita, Gene Kurosawa, Mariko Sumitomo, Susumu Tsutsumi, Keiko Ogawa, Kazuki Matsuda, Chiho Muramatsu, Noriko Satou, Masachika Azuma, Yoshinori Ukai, Kazuhiro Suzuki, Yoshikazu Kurosawa, Miho Tanaka, Mamoru Shiraishi
-
Patent number: 7572895Abstract: The invention provides further characterization of the disease and cancer-associated antigen, transferrin receptor. The invention also provides a novel family of antibodies that bind to the transferrin receptor, methods of diagnosing and treating various human cancers and diseases that express transferrin receptor.Type: GrantFiled: June 7, 2005Date of Patent: August 11, 2009Assignee: Raven Biotechnologies, Inc.Inventors: Jennie P. Mather, Penelope E. Roberts, Ronghao Li
-
Patent number: 7569356Abstract: The present invention relates to methods and compositions for the diagnosis and therapy of prostate cancer which utilize isolated polynucleotides corresponding to the human SGP28 gene, proteins encoded by the SGP28 gene and fragments thereof, and antibodies capable of specifically recognizing and binding to SGP28 proteins.Type: GrantFiled: November 18, 2004Date of Patent: August 4, 2009Assignee: Agensys, Inc.Inventors: Daniel E. H. Afar, Rene S. Hubert, Arthur B. Raitano, Steven Chappell Mitchell, Mary Faris, Aya Jakobovits
-
Patent number: 7569390Abstract: A general immunoglobulin-target assay system is provided, in which a positive outcome (the generation of a signal) depends only on the intracellular interaction of immunoglobulin with target. This can be accomplished for many immunoglobulins expressed in yeast and/or in mammalian cells and allows the selection of immunoglobulins which are capable of functioning in an intracellular environment.Type: GrantFiled: March 10, 2000Date of Patent: August 4, 2009Assignees: Medical Research Council, Scuola Internazionale Superiore Di Studi AvanzatiInventors: Tse Wai-Choi Eric, Terenos Rabbits, Antonio Cattaneo, Michela Visintin
-
Publication number: 20090191222Abstract: This disclosure characterizes the function and the expression of the human protein encoded by tm9sf4. The protein is highly expressed in malignant tumor cells and therefore is a novel marker for malignancy. Moreover, the protein is involved in the phagocytotic character of tumor cells. This disclosure provides methods and tools to diagnose and follow up malignancy of tumors. Furthermore, means to inhibit phagocytotic character of tumor cells as well as means to treat cancer are provided.Type: ApplicationFiled: January 26, 2009Publication date: July 30, 2009Applicant: Hansabiomed OUInventors: Francesco Lozupone, Stefano Fais
-
Publication number: 20090181009Abstract: Anti-NTB-A antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. Also described are methods of using such antibodies and antigen-binding regions to bind NTB-A and treat diseases, such as hematologic malignancies, which are characterized by expression of NTB-A.Type: ApplicationFiled: August 17, 2007Publication date: July 16, 2009Applicant: Nuvelo, Inc.Inventors: Arie Abo, Wouter Korver
-
Patent number: 7560242Abstract: Metadherin, a protein that controls metastasis, and variants of metadherin are described. DNA sequences encoding the same and methods of production are described. Therapies involving the application of metadherin, binding agents that bind to metadherin, such as antibodies, and expression modulating agents, such as siRNA, are described. The use of metadherin or metadherin variants for delivering desired substances to particular lung tissue is described. A method of diagnosing metastatic cells based on the presence of metadherin is described.Type: GrantFiled: November 10, 2004Date of Patent: July 14, 2009Assignee: The Burnham InstituteInventors: Erkki Ruoslahti, Darren M. Brown
-
Publication number: 20090175858Abstract: The invention relates to a crystal complex formed by the extracellular domain of EGF receptor (EGFR) and the Fab fragment of anti-EGFR antibody matuzumab (EMD 72000). Especially the invention relates to the identification of the epitope regions on said EGFR, which the antibody matuzumab recognizes as antigen an to which it specifically binds. The invention relates furthermore to protein, peptide and antibody structures which mimic the binding of matuzumab to its epitope region on EGFR, and may be used therefore, as EGFR antagonists with similar or improved properties as compared to matuzumab.Type: ApplicationFiled: October 2, 2008Publication date: July 9, 2009Applicants: Merck Patent GmbH, The Trustees of the University of PennsylvaniaInventors: Kathryn M. Ferguson, Thorsten Knoechel, Judith Schmiedel
-
Publication number: 20090170191Abstract: A novel gene (designated 84P2A9) and its encoded protein is described. While 84P2A9 exhibits prostate and testis specific expression in normal adult tissue, it is aberrantly expressed multiple cancers including prostate, testis, kidney, brain, bone, skin, ovarian, breast, pancreas, colon, lymphocytic and lung cancers. Consequently, 84P2A9 provides a diagnostic and/or therapeutic target for cancers, and the 84P2A9 gene or fragment thereof, or its encoded protein or a fragment thereof used to elicit an immune response.Type: ApplicationFiled: November 26, 2008Publication date: July 2, 2009Applicant: AGENSYS, INC.Inventors: Aya Jakobovits, Daniel E.H. Afar, Pia M. Challita-Eid, Elana Levin, Steve Chappell Mitchell, Rene S. Hubert
-
Publication number: 20090169572Abstract: The present invention relates to the use of cytotoxicity based on the effector function of anti-CDH3 antibodies. Specifically, the present invention provides methods and pharmaceutical compositions that comprise an anti-CDH3 antibody as an active ingredient for damaging CDH3-expressing cells using antibody effector function. Since CDH3 is strongly expressed in pancreatic, lung, colon, prostate, breast, gastric or liver cancer cells, the present invention is useful in pancreatic, lung, colon, prostate, breast, gastric or liver cancer therapies.Type: ApplicationFiled: February 28, 2007Publication date: July 2, 2009Applicant: Oncotherapy Science, Inc,Inventors: Shuichi Nakatsuru, Megumi Yoshikawa, Shinichi Hiroshima
-
Publication number: 20090170130Abstract: The present invention provides chemokine receptor antibodies that selectively bind to an activated form of the receptor but not to a non activated form of the receptor. In particular, the current invention provides phospho specific chemokine receptor antibodies. The antibodies can be used in several diagnostic, screening and purification methods.Type: ApplicationFiled: June 30, 2006Publication date: July 2, 2009Applicant: National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DHHS), U.S. Gov.Inventors: Joshua Rubin, Andrew Kung
-
Publication number: 20090162852Abstract: Overexpression of the gene, BAALC, in biological samples from a patient is prognostic for tumor aggressiveness and unfavorable patient outcome. The present invention provides polynucleotide primers and probes for assaying for overexpression of BAALC transcripts. Kits containing the primers and probes are also provided. Also provided are antibodies for assaying for overexpression of BAALC proteins as well as peptide immunogens for producing the anti-BAALC antibodies. The present invention also provides methods for characterizing acute myelogenous leukemia, chronic myelogenous leukemia and prostate cancer in a patient, base on detection of BAALC overexpression.Type: ApplicationFiled: October 20, 2008Publication date: June 25, 2009Applicant: THE OHIO STATE UNIVERSITY RESEARCH FOUNDATIONInventors: Stephan M. Tanner, Albert de la Chapelle
-
Publication number: 20090162284Abstract: Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-I and are substantially devoid of agonist activity toward the insulin-like growth factor-I receptor. These molecules can be conjugated to cytotoxic agents for use in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer. These molecules can also be labeled for in vitro and in vivo diagnostic uses, such as in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.Type: ApplicationFiled: October 15, 2008Publication date: June 25, 2009Inventors: Rajeeva SINGH, Daniel J. Tavares, Nancy E. Dagdigian
-
Patent number: 7550568Abstract: The present invention provides monoclonal antibodies that react against high molecular weight melanoma-associated antigen. These antibodies may be used for diagnostic and/or therapeutic purposes.Type: GrantFiled: February 28, 2008Date of Patent: June 23, 2009Assignee: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventor: Soldano Ferrone
-
Publication number: 20090155276Abstract: The present invention relates to novel sequences for use in detection, diagnosis and treatment of diseases, including cancer. The invention provides novel splice products of human DKKL-1 gene. The present invention provides methods of using polynucleotides having the novel splice products of the human DKKL-1 sequences, their corresponding gene products and modulators of the DKKL-1 splice products for the detection, diagnosis, prevention and/or treatment of associated cancers.Type: ApplicationFiled: March 30, 2006Publication date: June 18, 2009Inventors: Albert Lai, Robert Booher
-
Publication number: 20090155807Abstract: The invention provides methods and compositions useful for detecting mutations in c-met in lung cancer cells.Type: ApplicationFiled: February 9, 2009Publication date: June 18, 2009Applicant: GENENTECH, INC.Inventor: ROBERT L. YAUCH
-
Publication number: 20090148449Abstract: Isolated human monoclonal antibodies which bind to human CD38, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: ApplicationFiled: March 23, 2006Publication date: June 11, 2009Applicant: Genmab A/SInventors: Michel De Weers, Yvo Graus, Judith Oprins, Paul Parren, Jan Van De Winkel, Martine Van Vugt
-
Publication number: 20090148513Abstract: The present invention relates to a batch crystallization method for crystallizing anti-human TNFalpha (hTNFalpha) antibody and antibody fragments which allows the production of said antibody on an industrial scale; a method of controlling the size of antibody crystals, for example, crystals of anti-hTNFalpha antibody fragments, compositions containing said crystals as well as methods of use of said crystals and compositions.Type: ApplicationFiled: August 8, 2008Publication date: June 11, 2009Inventors: Wolfgang Fraunhofer, David W. Borhani, Gerhard Winter, Stefan Gottschalk
-
Publication number: 20090142346Abstract: A human monoclonal antibody against a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 3, its partial peptide, or a salt thereof, is useful as an agent for preventing/treating cancer, etc., an apoptosis inducer of cancer cells, a growth inhibitor of cancer cells, a cytotoxic agent against cancer cells through a host defense mechanism mediated by the Fc region of an antibody, and so on.Type: ApplicationFiled: October 6, 2006Publication date: June 4, 2009Applicant: Takeda Pharmaceutical Company LimitedInventors: Shuji Sato, Tsutomu Oshima, Tomofumi Kurokawa
-
Publication number: 20090142777Abstract: The invention discloses 424 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human Leukemia, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: Adaptor/Scaffold proteins, Cytoskeletal proteins, Cellular Metabolism enzymes, G Protein/GTPase Activating/Guanine Nucleotide Exchange Factor proteins, Immunoglobulin Superfamily proteins, Inhibitor proteins, Lipid Kinases, Nuclear DNA Repair/RNA Binding/Transcription proteins, Serine/Threonine Protein Kinases, Tyrosine Kinases, Protein Phosphatases, and Translation/Transporter proteins.Type: ApplicationFiled: October 5, 2007Publication date: June 4, 2009Inventors: Valerie Goss, Albrecht Moritz, Ting-Lei Gu, Kimberly Lee, Roberto Polakiewicz
-
Publication number: 20090142262Abstract: The present invention provides new methods for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating prostate cancer.Type: ApplicationFiled: August 27, 2008Publication date: June 4, 2009Inventors: Susan Salceda, Herve Recipon, Robert Cafferkey
-
Publication number: 20090136490Abstract: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Ovr110) antibodies that internalize upon binding to Ovr110 on a mammalian in vivo. The invention also encompasses compositions comprising an anti-Ovr110 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr110 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr110 antibodies. The invention encompasses a method of producing the anti-Ovr110 antibodies. Other aspects of the invention are a method of killing an Ovr110-expressing cancer cell, comprising contacting the cancer cell with an anti-Ovr110 antibody and a method of alleviating or treating an Ovr110 expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Ovr110 antibody to the mammal.Type: ApplicationFiled: November 10, 2005Publication date: May 28, 2009Applicant: DIADEXUS, INC.Inventors: Glenn Pilkington, Gilbert-Andre Keller, Wenlu Li, Timothy S. Burcham, Laura Corral, Iris Simon, Jackie Papkoff
-
Publication number: 20090136503Abstract: This invention relates generally to the preparation of TRAIL receptor-binding agents and uses of the same. In particular, the present invention relates to the preparation of anti-TRAIL receptor antibodies which recognize a common antigen determinant (i.e., epitope) shared by TRAIL-R1 and TRAIL-R2 receptors and their use for TRAIL receptor detection and modulation of TRAIL receptor-mediated function. The TRAIL receptor-binding agents are useful to induce apoptosis in human cancer cells. These targets may either express one or both TRAIL-R1 or TRAIL-R2. The invention provides for the use of the TRAIL receptor-binding agents of the invention in cancer therapy.Type: ApplicationFiled: April 29, 2007Publication date: May 28, 2009Inventors: Zheng Yu, Min Zhou, Enyun Shen, Xianzhao Jia, Yang Song
-
Publication number: 20090130106Abstract: The present invention relates generally to a set of synthetic immunointeractive molecules referred to herein as “demibodies” which are useful in targeting particular cells in a subject. More particularly, the present invention provides a set of demibodies wherein at least two molecules from within the set, each specific for a different antigen on a target cell, are required to interact together at the cell surface in order to form an active complex which directs demibody-mediated cellular or complement mediated cytotoxicity and/or reporter function and/or therapeutic activity. The demibodies of the present invention are useful in the targeting of particular cells such as cancer cells including leukemic cells, pathogens including malarial, bacterial and viral agents, and stem cells including embryonic and adult stem cells and pathogen cells. The present invention provides, therefore, methods of treatment, diagnosis and undertaking research and compositions comprising demibodies useful for same.Type: ApplicationFiled: November 29, 2006Publication date: May 21, 2009Applicant: The University of SydneyInventors: Richard Ian Christopherson, Jacqueline Mary Matthews, Joel Peter MacKay
-
Patent number: 7534428Abstract: The present invention relates to novel Tumor Necrosis Factor Receptor proteins. In particular, isolated nucleic acid molecules are provided encoding the human TNFR-6? & -6? proteins. TNFR-6? & -6? polypeptides and antibodies that bind TNFR-6? & -6? polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TNFR-6? & -6? activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.Type: GrantFiled: May 3, 2006Date of Patent: May 19, 2009Assignee: Human Genome Sciences, Inc.Inventors: Reiner L. Gentz, Reinhard Ebner, Guo-Liang Yu, Steven M. Ruben, Jian Ni, Ping Feng
-
Publication number: 20090123470Abstract: An isolated binding partner of a Cripto-1 protein, Pim-1 protein or an antigen present in a colon cancer cell lysate is described. The binding partner inhibits growth of one or more cancer cell types and may be used in an anti-cancer agent for treating cancer in a subject. The binding partner may also be used in a method of inducing apoptosis in a cancer cell, as well as in a method of sensitizing a cancer cell to a cytotoxic compound. In addition, a cancer vaccine is described wherein the vaccine comprises a Cripto-1 protein (or an antigenic fragment thereof), Pim-1 protein (or an antigenic fragment thereof) or an antigen present in a colon cancer cell lysate or, alternatively, comprises an expressible DNA molecule encoding a Cripto-1 protein (or an antigenic fragment thereof), Pim-1 protein (or an antigenic fragment thereof) or an antigen present in a colon cancer cell lysate.Type: ApplicationFiled: November 20, 2007Publication date: May 14, 2009Applicant: The Macfarlane Burnet Istitute for Medical Research and Public Health Ltd.Inventors: Ian Farquhar Campbell McKenzie, Pei Xiang Xing, Xiu Feng Hu
-
Publication number: 20090123483Abstract: Antibodies, or antigen-binding fragment thereof, which bind to a CCR7 receptor are capable of selectively killing, impairing migration and/or blocking dissemination of tumour cells expressing a CCR7 receptor. Use of said antibodies for killing or for inducing apoptosis of said tumour is disclosed, thus providing an alternative therapy for treatment of cancer which tumour cells express a CCR7 receptor.Type: ApplicationFiled: July 5, 2006Publication date: May 14, 2009Applicant: UNIVERSIDAD AUTONOMA DE MADRIDInventors: Cecilia Munoz Calleja, Manuel Jesus Alfonso Perez, Sonia Lopez Giral
-
Patent number: 7531171Abstract: The present invention provides antibodies that specifically bind to P2X7 receptors and distinguish between function and non-functional P2X7 receptors, pharmaceutical compositions and kits containing the antibodies, and methods of using the antibodies for the detection, diagnosis and treatment of disease conditions.Type: GrantFiled: January 2, 2008Date of Patent: May 12, 2009Assignee: Intreat Pty LimitedInventors: Julian Alexander Barden, Angus Gidley-Baird
-
Publication number: 20090117036Abstract: GPR64 antibody compositions are provided. These antibodies may be used for diagnosis or treatment of cancer, especially ovarian cancer, Ewing's sarcoma, uterine cancer, and other GPR64 expressing tumor types.Type: ApplicationFiled: September 3, 2008Publication date: May 7, 2009Inventors: Debbie Law, Qi Wang, Robert BuBridge, Vinay Bhaskar
-
Patent number: 7527969Abstract: The invention provides the identification and characterization of disease and cancer-associated antigen, RAAG10. The invention also provides a family of monoclonal antibodies that bind to antigen RAAG10, methods of diagnosing and treating various human cancers and diseases that express RAAG10.Type: GrantFiled: June 19, 2003Date of Patent: May 5, 2009Assignee: Raven biotechnologies, inc.Inventors: Jennie P. Mather, Ronghao Li, Zhuangyu Pan, Penelope E. Roberts
-
Patent number: 7528239Abstract: A protein designated TRAIL receptor binds the protein known as TNF-Related Apoptosis-Inducing Ligand (TRAIL). The TRAIL receptor finds use in purifying TRAIL or inhibiting activities thereof. Isolated DNA sequences encoding TRAIL-R polypeptides are provided, along with expression vectors containing the DNA sequences, and host cells transformed with such recombinant expression vectors. Antibodies that are immunoreactive with TRAIL-R are also provided.Type: GrantFiled: August 20, 1999Date of Patent: May 5, 2009Assignee: Immunex CorporationInventors: Charles Rauch, Henning Walczak
-
Publication number: 20090104185Abstract: The present invention provides Mycoplasma toxins, biologically active fragments/domains of the toxins, antibodies to the toxins, therapeutic fusion proteins comprising the toxins and/or biologically active fragments/domains of the toxins and nucleic acids encoding the toxins and fusion proteins. Also provided are methods of treating and/or preventing diseases and disorders using the compositions provided herein.Type: ApplicationFiled: March 31, 2006Publication date: April 23, 2009Inventors: Joel Barry Baseman, Thirumalai Rengasamy Kannan
-
Publication number: 20090104631Abstract: The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.Type: ApplicationFiled: July 8, 2008Publication date: April 23, 2009Applicants: The Regents of the University of California, Agensys, Inc.Inventors: Robert E. Reiter, Owen N. Witte, Douglas C. Saffran, Aya Jakobovits
-
Publication number: 20090104196Abstract: The invention relates to antibodies for use for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal and to pharmaceutical and diagnostical compositions comprising such antibodies. The invention also relates to a method for identifying and/or scoring prostate carcinomas. Furthermore, the invention relates to the use of at least one siRNA (“short interfering RNA”) and/or at least one anti-LSD1 antibody for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal or for the manufacture of a medicament for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal. The invention also relates to a pharmaceutical composition for controlling the androgen receptor-dependent gene expression, comprising an effective dose of at least one siRNA and/or at least one anti-LSD1 antibody suitable for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal.Type: ApplicationFiled: July 13, 2006Publication date: April 23, 2009Inventors: Roland Schuele, Erich Metzger, Reinhard Buettner
-
Publication number: 20090104215Abstract: Antibodies which target clusterin, a protein involved in the epithelial-to-mesenchymal transition of carcinoma cells, are identified and characterized. The antibodies may be used to modulate tumour cell activity through binding to clusterin.Type: ApplicationFiled: September 13, 2006Publication date: April 23, 2009Inventors: Irena Ekiel, Maureen D. O'Connor-McCourt, Christiane Cantin, Anne E.G. Lenferink
-
Patent number: 7521053Abstract: Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.Type: GrantFiled: October 10, 2002Date of Patent: April 21, 2009Assignees: Amgen Inc., Medarex, Inc.Inventor: Jonathan Daniel Oliner
-
Publication number: 20090099340Abstract: The invention discloses 214 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human carcinoma, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: Adaptor/Scaffold proteins, Cytoskeleton proteins, GTP Signaling proteins, Kinases, Metabolism proteins, Phosphatases/Phospho-diesterases/Proteases, Receptor proteins, RNA Processing proteins, Transcription proteins, Translation proteins, Transporter proteins, and Ubitquitin proteins, as well as other protein types.Type: ApplicationFiled: October 12, 2007Publication date: April 16, 2009Inventors: Ailan Guo, Klarisa Rikova, Albrecht Moritz, Yu Li, Charles Farnsworth, Kimberly Lee, Roberto Polakiewicz
-
Publication number: 20090098125Abstract: The present invention is directed to the diagnosis and treatment of diseases, preferably the inhibition of tumor growth and its progression to metastatic sites, through the inhibition of the production of PTHrP, its isoforms or PTHrP signalling. The present invention is also directed to methods of inhibiting the PTHrP1-173 isoform through antagonists thereof, including monoclonal antibodies and siRNA directed there against. The invention may be applicable to many disease states, including but not limited to several types of cancer (such as breast, lung, prostate, melanoma and squamous) expressing PTHrP and its isoforms, alone or in combination with other therapeutic agents.Type: ApplicationFiled: August 17, 2007Publication date: April 16, 2009Inventors: Richard Kremer, Dao Chao Huang
-
Publication number: 20090098629Abstract: A novel testis-specific gene expressed in human prostate cancer, designated 22P4F11, is described. Analysis of 22P4F11 mRNA expression in normal prostate, prostate tumor xenografts, and a variety of normal tissues indicates that the expression of this gene is testis specific in normal tissues. The 22P4F11 gene is also expressed in human prostate tumors, in some cases at high levels. A full length cDNA encoding 22P4F11 is provided. The 22P4F11 transcript and/or protein may represent a useful diagnostic marker and/or therapeutic target for prostate cancer.Type: ApplicationFiled: September 16, 2008Publication date: April 16, 2009Inventors: Daniel E. AFAR, Rene S. Hubert, Stephen Chappell Mitchell
-
Patent number: 7517967Abstract: The present invention relates to monoclonal antibody 1A7. This is an anti-idiotype produced by immunizing with an antibody specific for ganglioside GD2, and identifying a hybridoma secreting antibody with immunogenic potential in a multi-step screening process. Also disclosed are polynucleotide and polypeptide derivatives based on 1A7, including single chain variable region molecules and fusion proteins, and various pharmaceutical compositions. When administered to an individual, the 1A7 antibody overcomes immune tolerance and induces an immune response against GD2, which comprises a combination of anti-GD2 antibody and GD2-specific T cells. The invention further provides methods for treating a disease associated with altered GD2 expression, particularly melanoma, neuroblastoma, glioma, soft tissue sarcoma, and small cell carcinoma. Patients who are in remission as a result of traditional modes of cancer therapy may be treat with a composition of this invention in hopes of reducing the risk of recurrence.Type: GrantFiled: March 23, 2005Date of Patent: April 14, 2009Assignee: University of Kentucky Research FoundationInventors: Malaya Chatterjee, Kenneth A. Foon, Sunil K. Chatterjee
-
Publication number: 20090092598Abstract: The present invention provides a composition comprising naked humanized, chimeric, and human anti-CEA antibodies and a therapeutic agent, which is useful for treatment of CEA expressing cancers and other diseases, and methods of use in treatment using this composition.Type: ApplicationFiled: October 31, 2007Publication date: April 9, 2009Inventors: David M. Goldenberg, Hans J. Hansen
-
Patent number: 7514538Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.Type: GrantFiled: February 14, 2008Date of Patent: April 7, 2009Assignee: Genentech, Inc.Inventors: Audrey Goddard, Austin L. Gurney, Paul Polakis, Victoria Smith, William I. Wood, Thomas D. Wu, Zemin Zhang